Please assess the completion status of the following clinical trial:

Trial Title: Mycotic Ulcer Treatment Trial I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a corneal ulcer at presentation~* Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)~* Visual acuity between 6/12 (20/40, logMAR 0.3) and 6/120 (20/400, logMAR 1.3)~* The patient must be able to verbalize a basic understanding of the study after it is explained to the patient, as determined by physician examiner. This understanding must include a commitment to return for follow-up visits.~* Willingness to be treated as an inpatient or to be treated as an outpatient and return every 3 days +/- 1 day until re-epithelialization and every week to receive fresh medication for 3 weeks~* Appropriate consent~Exclusion Criteria:~* Impending perforation~* Evidence of bacteria on Gram stain at the time of enrollment~* Evidence of acanthamoeba by stain~* Evidence of herpetic keratitis by history or exam~* Corneal scar not easily distinguishable from current ulcer~* Age less than 16 years (before 16th birthday)~* Bilateral ulcers~* Previous penetrating keratoplasty in the affected eye~* Pregnancy (by history or urine test) or breast feeding (by history)~* Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)~* Acuity worse than 6/120 (20/400) or better than 6/12 (20/40) in the study eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA can be used for enrollment)~* Known allergy to study medications (antifungal or preservative)~* No light perception in the affected eye~* Not willing to participate

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Natamycin (Type: ACTIVE_COMPARATOR): None
- Topical Voriconazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).